Figure 2.
![Clinical outcomes after alloBMT are associated with VAF pretransplant CH. Kaplan-Meier curves of (A) OS and (B) PFS; cumulative incidence of (C) NRM and (D) relapse by CH-negative or CH-positive. Estimates in CH positive group were further stratified by ([VAF] 1%-10% and ≥10%).](https://ash.silverchair-cdn.com/ash/content_public/journal/bloodadvances/8/14/10.1182_bloodadvances.2023011761/1/blooda_adv-2023-011761-gr2.jpeg?Expires=1724949600&Signature=paP2nYIna2ebmbABeB-asC6KnJY0R65TVKhV1KPyH1zJH7FBUHAsgli5Uuyc1l8uU1jMBIC7PPuY3A0tm-Zgkt8z4EQ39tJ9q3cy9ZRKkhPvXzVPOXxZNoedG3mDvu4pO7B9f8e1dpAdhpyvbW3jHFw~F85NKLzFdyuO7ggRgfG4wUZMm6e68Tau7QgPh~0Tujjn4VJlvjjY5DU0JLR4NGjs95VeelCSY-hQq5m6S4xr8Q-CZoSfNnbl3Ghlw08nZ5tN6HhQY3oV0PpmMUglbxT4Km5CAT39lBhXUTdjTfYULq7jfPG2l6vSzVoc7auNK4jrcoo3E6KHomi50BaiSg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Clinical outcomes after alloBMT are associated with VAF pretransplant CH. Kaplan-Meier curves of (A) OS and (B) PFS; cumulative incidence of (C) NRM and (D) relapse by CH-negative or CH-positive. Estimates in CH positive group were further stratified by ([VAF] 1%-10% and ≥10%).
